For readers interested in next-generation GLP-1-based therapies for diabetes, obesity and more, here's a review
nature.com/articles/s41...
rdcu.be/fnl3W
Novel drug targets in 2025
www.nature.com/articles/d41...
This new article highlights 11 targets not previously modulated by approved drugs
A guide to effective drug development through nonprofit models
www.nature.com/articles/d41...
Patient organizations are reshaping rare disease drug development. Based on a survey, interviews and experience, this article discusses how to direct resources toward drug development goals
Our June issue is live! Read about the therapeutic potential of orphan GPCRs, wearable technologies in clinical trials for drug development, a renaissance in targeting the PI3K/AKT/mTOR pathway and more here www.nature.com/nrd/volumes/...
Therapeutic and prophylactic strategies for Ebola caused by Bundibugyo virus
www.nature.com/articles/d41...
This new article argues that the ongoing Ebola outbreak should be a turning point for moving R&D towards species-inclusive and broadly applicable filovirus countermeasures
Antiviral peptide nabs FDA approval for hepatitis delta virus infection
www.nature.com/articles/d41...
Gilead’s bulevirtide is the first treatment for the potentially fatal infection
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments. www.statnews.com/2026/06/08/a...
For readers interested in inhibitors of the JAK-STAT pathway as drugs for immunological and haematological diseases, here's a recent comprehensive review
www.nature.com/articles/s41...
rdcu.be/foHob
Evolution of the psoriasis therapy landscape
www.nature.com/articles/d41...
This new article analyses the pipeline of drugs for psoriasis and their market impact, highlighting the growing importance of oral therapies
The unglamourous AI wins that are quietly transforming drug discovery and development
nature.com/articles/d41...
David Reese, Amgen’s inaugural Chief Technology Officer, discusses how inconspicuous AI achievements stand to transform drug discovery
Nature Reviews Drug Discovery
Nature Reviews Drug Discovery
Nature Reviews Drug Discovery
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.
David Reese, Amgen’s inaugural Chief Technology Officer, discusses how inconspicuous AI achievements stand to transform drug discovery.
nature.com
The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway mediates cellular responses to cytokines and growth factors, and its dysregulation plays a role in various disord...
